Category: 1317-39-1

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1317-39-1,Copper(I) oxide,as a common compound, the synthetic route is as follows.

3-Chloro-4-nitro-benzonitrile Sodium nitrite (6.78 g in water (40 mL) at 0 C.) was slowly added to a solution of 4-amino-3-chloro-benzonitrile (10.5 g) in water (30 mL) and concentrated hydrochloric acid (30 mL) also at 0 C. After 10 minutes the solution was poured onto a suspension of cuprous oxide (3.48 g) and sodium nitrite (31.69 g) in water (100 mL) at 0 C. The ensuing mixture was stirred at 0 C. for 1 hour then at 23 C. for 1 hour. The resulting mixture was extracted with dichloromethane and the organic layer washed with saturated sodium chloride. The separated organic layer was dried over sodium sulfate and then concentrated to give 3-chloro-4-nitro-benzonitrile (11.31 g).

1317-39-1, 1317-39-1 Copper(I) oxide 10313194, acopper-catalyst compound, is more and more widely used in various fields.

Reference£º
Patent; Pfizer Inc.; US2003/78432; (2003); A1;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

Name is Copper(I) oxide, as a common heterocyclic compound, it belongs to copper-catalyst compound, and cas is 1317-39-1, its synthesis route is as follows.,1317-39-1

3-Chloro-4-nitro-benzonitrile Sodium nitrite (6.78 g in water (40 mL) at 0 C.) was slowly added to a solution of 4-amino-3-chloro-benzonitrile (10.5 g) in water (30 mL) and concentrated hydrochloric acid (30 mL) also at 0 C. After 10 minutes the solution was poured onto a suspension of cuprous oxide (3.48 g) and sodium nitrite (31.69 g) in water (100 mL) at 0 C. The ensuing mixture was stirred at 0 C. for 1 hour then at 23 C. for 1 hour. The resulting mixture was extracted with dichloromethane and the organic layer washed with saturated sodium chloride. The separated organic layer was dried over sodium sulfate and then concentrated to give 3-chloro-4-nitro-benzonitrile (11.31 g).

With the complex challenges of chemical substances, we look forward to future research findings about Copper(I) oxide

Reference£º
Patent; Pfizer Inc.; US2003/78432; (2003); A1;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

1317-39-1, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1317-39-1, name is Copper(I) oxide, introducing its new discovery.

Oxime derivatives

The invention concerns oxime derivatives of the formula I STR1 wherein R4 is hydrogen, (1-4C)alkyl, halogeno-(2-4C)alkyl, hydroxy-(2-4C)alkyl, cyano-(1-4C)alkyl, phenyl or phenyl-(1-4C)alkyl; R5 is hydrogen, (1-4C)alkyl, halogeno-(2-4C)alkyl, hydroxy-(2-4C)alkyl, cyano-(1-4C)alkyl, phenyl or phenyl-(1-4C)alkyl, or a heteroaryl moiety selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, oxazolyl and thiazolyl; A4 is (1-4C)alkylene; Ar1 is phenylene, pyridinediyl or pyrimidinediyl; A1 is a direct link to X1 or A1 is (1-4C)alkylene; X1 is oxy, thio, sulphinyl or sulphonyl; Ar2 is phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl or thiazolediyl; R1 is hydrogen, (1-4C)alkyl, (3-C)alkenyl or (3-4C)alkynyl; and R2 and R3 together form a group of the formula –A2 –X2 –A3 — wherein each of A2 and A3 is independently (1-3C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1317-39-1, name is Copper(I) oxide, introducing its new discovery. 1317-39-1

Triazapentadienes as acaricides

Certain heteroaryl triazapentadienes with acaricidal properties and their preparation are described.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”